Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration, but substantial evidence indicates that non-cell-autonomous mechanisms involving glial cells—astrocytes, microglia, and oligodendrocytes—play critical roles in disease progression. This page reviews current understanding of glial contributions to ALS and the critical question of which pathways are causally involved versus reactive to motor neuron injury.
The central question driving this research area is whether glial cell dysfunction is a primary driver of ALS pathogenesis or merely a secondary response to primary motor neuron injury. Distinguishing causal from reactive mechanisms has profound implications for therapeutic development.
Astrocytes are the most abundant glial cells in the central nervous system and perform essential homeostatic functions:
In ALS, astrocytes undergo dramatic phenotypic changes:
| Evidence Type | Supports Causal | Supports Reactive |
|---|---|---|
| SOD1 mouse models | Mutant astrocytes accelerate disease when wild-type neurons transplanted | Reactive changes appear after neuron loss |
| iPSC models | Astrocyte toxicity is transmissible to healthy neurons | Phenotype varies with disease stage |
| Human postmortem | Early EAAT2 loss in presymptomatic cases | Reactive changes correlate with progression |
Key studies supporting a causal role include:
Microglia exhibit complex activation states in ALS that span a spectrum[5]:
Strong genetic evidence supports microglia as causal contributors:
| Evidence | Interpretation |
|---|---|
| TREM2/CD33 genetics | Supports causal - genetic variants directly modify disease |
| Depletion studies | Supports causal - removal alters trajectory |
| Postmortem correlation | Supports reactive - activation correlates with neuron loss |
| Temporal studies | Mixed - some early changes, some late |
Oligodendrocytes provide critical support to motor neurons:
| Finding | Evidence Quality | Implication |
|---|---|---|
| Early OLIG2+ cell loss | Strong (human, mouse) | Causal candidate |
| Myelin abnormalities | Moderate | May be secondary |
| Metabolic coupling loss | Moderate | Therapeutic target |
| Autophagy defects | Strong | Contributes to dysfunction |
Recent research on autophagy dynamics in SOD1 oligodendrocytes revealed that oligodendrocytes mount effective compensatory autophagic responses to combat mutant SOD1, but significant dysfunctions persist in other glial types[13].
The relationship between astrocytes and microglia is bidirectional:
Motor Neuron Injury
↓
Astrocyte Activation
↓ ↘
Secreted Factors Microglial Priming
(IL-1β, TNF-α) ↓
←←←←←←←←← Enhanced Neuroinflammation
↓
Neuronal Death
Key mediators:
A landmark 2024 study demonstrated that microglial ferroptotic stress causes non-cell autonomous neuronal death in co-culture experiments, revealing a novel mechanism by which glial dysfunction directly harms neurons[14].
| Approach | Target | Stage | Evidence Level |
|---|---|---|---|
| TREM2 modulation | DAM pathway | Preclinical | Strong genetic |
| Microglial depletion | CSF1R | Preclinical | Moderate |
| Astrocyte glutamate transport | EAAT2 | Clinical (failed) | Mixed |
| NAD+ boosting | Sirt2, PARP | Preclinical | Promising |
| Oligodendrocyte rescue | MBP, Mbp | Preclinical | Early |
| IL-10 delivery | Anti-inflammatory | Preclinical | Moderate |
Temporal sequence: What initiates glial dysfunction—cell-autonomous motor neuron pathology or primary glial triggers?
Cell-type hierarchy: Which glial cell type is most critical for disease initiation versus propagation?
Tractability: Can we develop therapies that modulate glial function without compromising CNS homeostasis?
Biomarkers: What circulating or imaging markers reliably reflect glial contribution?
Causal mechanistic links: Which specific molecular pathways in glia are directly pathogenic versus compensatory?
** Heterogeneity**: How do glial contributions differ between genetic (SOD1, C9orf72, FUS, TARDBP) and sporadic ALS?
The evidence for non-cell-autonomous glial contributions to ALS is substantial, with the strongest case for causality coming from genetic studies (TREM2, CD33, CX3CR1 variants) and experimental modulation (astrocyte/microglial depletion). However, the field still struggles to definitively separate primary causal mechanisms from secondary reactive responses. Resolving this distinction is critical for developing effective glial-targeted therapies.
Recent research on glial contributions to ALS has advanced understanding of non-cell-autonomous mechanisms:
Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992. ↩︎ ↩︎
Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutant SOD1 release signaling molecules that are toxic to motor neurons. Nat Neurosci. 2007. ↩︎
Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited ALS. Nat Neurosci. 2008. ↩︎
Zhou Y, Liu W, Zhang L, et al. Astrocyte contributions to non-cell autonomous neuronal death through mechanisms involving microglia. Proc Natl Acad Sci. 2024. ↩︎
Liao B, Zhao W, Beers DR, et al. Emerging roles of microglia in ALS. Cell Mol Neurobiol. 2022. ↩︎
Cady J, Karch CM, Han J, et al. 'TREM2 variants in ALS: a genome-wide association study'. Lancet Neurol. 2015. ↩︎
Jones MR, Simmons NB, Traynor BJ. 'CD33 and ALS: a protective variant?'. Neurology. 2015. ↩︎
Raposo C, Zabel R, Cunningham J, et al. CX3CR1 polymorphisms and ALS. Neurology. 2015. ↩︎
van Doorn J, Nijthof JM, van der Linde R, et al. ABI3 and ALS risk. Nat Neurosci. 2023. ↩︎
Pyonteck SM, Akkari L, Bowman RL, et al. CSF1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013. ↩︎
Cardona AE, Piao Y, Szabo AC, et al. The fractalkine receptor (CX3CR1) modulates disease severity in animal models of ALS. J Neurosci. 2006. ↩︎
Clarke BE, Ziff OJ, Tyzack G, et al. VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB. Acta Neuropathol Commun. 2024. ↩︎
Perera ND, De Silva S, Tomas D, et al. Mapping Glial Autophagy Dynamics in an Amyotrophic Lateral Sclerosis Mouse Model Reveals Microglia and Astrocyte Autophagy Dysfunction. Glia. 2025. ↩︎
Microglial ferroptotic stress causes non-cell autonomous neuronal death. Cell Death Differ. 2024. ↩︎